Form 4: OnKure Therapeutics Director Isaac Manke Acquires 6,311 Shares Through RSU Grant

OnKure Therapeutics, Inc. Director Isaac Manke has acquired 6,311 shares of Class A Common Stock through the vesting of restricted stock units, part of the company's director compensation policy.

Summary

• Isaac Manke, a Director of OnKure Therapeutics, Inc. (OKUR), acquired 6,311 shares of Class A Common Stock.
• The acquisition occurred on June 30, 2025, and was made through the vesting of fully vested restricted stock units (RSUs).
• These RSUs were granted to Mr. Manke in lieu of a quarterly cash retainer, a choice made by Mr. Manke under the Issuer's Outside Director Compensation Policy.
• Each RSU represents a contingent right to receive one share of Class A Common Stock, with the acquisition price noted as $0.
• Following this transaction, Isaac Manke directly beneficially owns 9,780 shares of Class A Common Stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The document reports a standard, pre-planned insider transaction related to director compensation. The director's election to receive equity over cash is a positive for alignment, but the filing itself is routine and does not indicate significant positive or negative news beyond this.

Positives

• Director Isaac Manke's election to receive equity (RSUs) instead of cash for compensation aligns his interests more closely with shareholders.
• The acquisition of 6,311 shares increases the director's direct beneficial ownership to 9,780 shares, demonstrating continued investment in the company.

Negatives

• The issuance of new shares, even as RSUs, can lead to minor dilution for existing shareholders, though this is a standard part of equity compensation plans.

Risks

• Equity compensation ties a portion of the director's compensation directly to the company's stock performance, exposing them to market fluctuations.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports a past insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice across various industries, including the biotechnology and pharmaceutical sectors where OnKure Therapeutics operates. Such filings provide transparency regarding executive and director equity holdings but do not typically reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as Restricted Stock Units (RSUs), in lieu of or in addition to cash retainers, is a widely accepted standard across publicly traded companies, particularly in the U.S. This aligns director interests with shareholder value.
• While specific compensation amounts vary by company size, industry, and individual director responsibilities, the mechanism of RSU grants for non-employee directors is common.
• For example, many biotech companies of similar market capitalization to OnKure Therapeutics utilize similar equity-based compensation structures for their board members to attract and retain talent and foster long-term commitment.

Corporate Governance

Related Party Transactions

• The acquisition of 6,311 shares by Director Isaac Manke from OnKure Therapeutics, Inc. through RSU vesting is a related party transaction, as it involves a transaction between the company and one of its directors as part of a compensation arrangement.

Stakeholder Impact

• Shareholders: The transaction aligns the director's interests with shareholders by increasing his equity stake. There is a minor dilutive effect from the issuance of new shares, which is typical for equity compensation.
• Employees: No direct impact on employees is mentioned.
• Customers: No direct impact on customers is mentioned.
• Suppliers: No direct impact on suppliers is mentioned.
• Creditors: No direct impact on creditors is mentioned.

Next Steps

• No specific future actions, events, or milestones are mentioned in this Form 4 filing beyond the reported transaction.

Key Dates

Keywords

OnKure Therapeutics, OKUR, Isaac Manke, Form 4, SEC filing, insider transaction, restricted stock units, RSU, director compensation, equity compensation, beneficial ownership, Rule 10b5-1